Abstract
The Met proto-oncogene encodes MET tyrosine kinase protein which is a receptor for hepatocyte growth factor/scatter factor (HGF/SF). HGF binds to and activates MET to regulate diversified cellular and molecular activities such as proliferation, motility, differentiation, and survival. Aberration of HGF/MET signaling plays a proven role in promoting cancer initiation and malignant progression, providing a strong rationale for targeting the MET signaling pathway in the treatment of cancer. Several anti-HGF and anti-MET monoclonal antibodies, as well as small-molecule inhibitors of MET, are being evaluated in clinical trials for the treatment of various cancers. In this chapter, we discuss the role of HGF/MET signaling in cancer development and progression, the strategies for targeting MET signaling, as well as the promises and challenges of MET-targeted therapeutics.
| Original language | American English |
|---|---|
| Title of host publication | Current Human Cell Research and Applications |
| Publisher | Springer Publishing Company |
| Chapter | 8 |
| Pages | 151-181 |
| DOIs | |
| State | Published - Nov 17 2017 |
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS